A Closer Look At The Research Behind MIRE Therapy
- Volume 20 - Issue 7 - July 2007
- 12408 reads
- 0 comments
Monochromatic infrared light energy therapy is a multimillion-dollar industry. If this is a therapy that really works, we need to provide it aggressively for all of our patients with diabetes who are “at risk” for foot ulceration.
However, if the therapy does not work, we need to make sure healthcare resources are not wasted. We are the gatekeepers in many respects and prescribing expensive therapy that is ineffective or, at best, unproven is not a benefit to the patient or our profession.
At first glance, the literature appears to support the use of MIRE to improve peripheral neuropathy among patients with diabetes. However, there are a number of concerns about the existing science.
The quality of the clinical data is suspect and the ability of therapy to “reverse neuropathy” and prevent foot complications (such as ulceration, infection and amputation) related to sensory neuropathy is unproven. Further research needs to address design and analysis concerns.
Editor’s note: For further reading, see “Current And Emerging Options For Treating Diabetic Neuropathy” in the March 2005 issue of Podiatry Today.